Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)
- PMID: 18804762
- PMCID: PMC2688903
- DOI: 10.1016/j.atherosclerosis.2008.07.031
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)
Abstract
Aims: The aim of the present study was to investigate the association of high-sensitivity C-reactive protein (CRP), interleukin-6 (IL-6) and lipoprotein-associated phospholipase A2 (Lp-PLA2) with the extent of calcified coronary atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
Materials and results: This is a cross-sectional study of 306 subjects aged 40years or older who were enrolled into the veterans affairs diabetes trial (VADT). Calcified coronary atherosclerosis was assessed using electron beam computed tomography scored by the Agatston method. Clinical parameters, traditional cardiovascular risk factors and plasma levels of CRP, IL-6 and Lp-PLA2 were measured at the time of the scan. Coronary artery calcium (CAC) scores increased stepwise across increasing categories of IL-6, but did not change across increasing categories of CRP and Lp-PLA2. After adjustment for traditional cardiovascular risk factors, IL-6 was significantly associated with CAC scores (p=0.05). The association between IL-6 and CAC was largely in those with lower (below the median) abdominal artery calcium (AAC) levels (p=0.04).
Conclusions: Despite a generally higher level of systemic inflammation in T2DM, the inflammatory marker IL-6 remained significantly associated with CAC score, particularly in those subjects with lower AAC scores.
Conflict of interest statement
Figures


Similar articles
-
Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT).Diabetes Care. 2010 Dec;33(12):2642-7. doi: 10.2337/dc10-1388. Epub 2010 Aug 31. Diabetes Care. 2010. PMID: 20807873 Free PMC article.
-
Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study.Clin Chem. 2008 Dec;54(12):1975-81. doi: 10.1373/clinchem.2008.107359. Epub 2008 Oct 2. Clin Chem. 2008. PMID: 18832472
-
Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.Diabetes. 2009 Nov;58(11):2642-8. doi: 10.2337/db09-0618. Epub 2009 Aug 3. Diabetes. 2009. PMID: 19651816 Free PMC article.
-
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.Vasc Health Risk Manag. 2006;2(2):153-6. doi: 10.2147/vhrm.2006.2.2.153. Vasc Health Risk Manag. 2006. PMID: 17319459 Free PMC article. Review.
-
[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].Acta Med Croatica. 2010 Oct;64(4):237-45. Acta Med Croatica. 2010. PMID: 21688606 Review. Croatian.
Cited by
-
HIV-1, reactive oxygen species, and vascular complications.Free Radic Biol Med. 2012 Jul 1;53(1):143-59. doi: 10.1016/j.freeradbiomed.2012.03.019. Epub 2012 Apr 21. Free Radic Biol Med. 2012. PMID: 22564529 Free PMC article. Review.
-
Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes.Diabetes Care. 2018 Mar;41(3):570-576. doi: 10.2337/dc17-1740. Epub 2017 Dec 5. Diabetes Care. 2018. PMID: 29208654 Free PMC article.
-
Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases.Cardiol Discov. 2023 Sep;3(3):166-182. doi: 10.1097/CD9.0000000000000096. Epub 2023 Jul 27. Cardiol Discov. 2023. PMID: 38152628 Free PMC article.
-
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.Int J Mol Sci. 2021 May 28;22(11):5770. doi: 10.3390/ijms22115770. Int J Mol Sci. 2021. PMID: 34071276 Free PMC article. Review.
-
Inflammation, a link between obesity and cardiovascular disease.Mediators Inflamm. 2010;2010:535918. doi: 10.1155/2010/535918. Epub 2010 Aug 5. Mediators Inflamm. 2010. PMID: 20847813 Free PMC article.
References
-
- Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843. - PubMed
-
- Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006;95:511–518. - PubMed
-
- Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study 1. Circulation. 2004;109:837–842. - PubMed
-
- Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol. 2002;40:1761–1768. - PubMed
-
- Stewart RA, White HD, Kirby AC, et al. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation. 2005;111:1756–1762. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous